Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment
Year: 2019
Type: article
Abstract: CITATION: de Vos, M. et al. 2019. Bedaquiline microheteroresistance after cessation of tuberculosis treatment. New England Journal of Medicine, 380(22):2178-2180. doi:10.1056/NEJMc1815121
Source: New England Journal of Medicine
DOI: 10.1056/nejmc1815121
Institutions: Stellenbosch University, Translational Genomics Research Institute, Médecins Sans Frontières, National Health Laboratory Service, Centers for Disease Control and Prevention, Critical Path Institute, University of California, San Francisco, University of Antwerp, South African Medical Research Council, University of Cape Town
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Bill and Melinda Gates Foundation, Wellcome Trust, National Research Foundation, South African Medical Research Council, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Fonds Wetenschappelijk Onderzoek, National Institutes of Health, National Institute of Allergy and Infectious Diseases, NIH Clinical Center, European and Developing Countries Clinical Trials Partnership
Awards: G1720747347, G4294709403, G4450764517, G5079299209, A systems approach to evaluating prospects for the control of drug-resistant tuberculosis in Khayelitsha, South Africa., Spatio-temporal changes and evolution of extensively drug resistant tuberculosis across Western Cape Province, South Africa, Critical Path Institute - to accelerate the development of a safer, faster-acting and more efficacious drug regimen(s) for the treatment of tuberculosis (TB) by curating dat..., G9000127343
OpenAlex ID: W2947442172